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Flavomycin is a commercially available antimicrobial growth promoter and an authorized
additive for feeding stuffs in the EU and in the USA. As most antibiotically active products
biosynthesized by microorganisms, it contains not only a single active compound but is a
complex mixture of structurally closely related substances. Multistage matrix-assisted laser
desorption/ionization-ion trap/reflectron time-of-flight mass spectrometry (MALDI-IT/
RTOF-MS) and liquid chromatography-electrospray ionization-ion trap-mass spectrometry
(LC-ESI-IT-MS) were utilized for a detailed analysis of the constituents of the Flavomycin
complex based on low-energy collision induced dissociation (CID). An optimal sample
preparation for negative ion vacuumMALDI-MS for this compound class was developed. The
MALDI-IT/RTOF-MS2 and -MS3 analysis starting with the precursor [M  H] ions of these
interesting phosphoglycolipids, named moenomycins, yielded a large variety of product ions
that facilitated the structural characterization of this class of compounds. Based on the derived
CID fragmentation pathway of the five known major constituents, namely moenomycin A,
moenomycin A12, moenomycin C4, moenomycin C3. and moenomycin C1, four not yet
described moenomycin-type constituents could be characterized. They were assigned
as 4F-demethyl-6E-O-de--D-glucopyranosyl-moenomycin A, 6B-N-de(2-hydroxy-5-oxo-1-
cyclopenten-1-yl)-moenomycin A, 6B-hydroxy-6B-de[N-(2-hydroxy-5-oxo-1-cyclopenten-1-
yl)amino]-moenomycin A, and 6C-hydroxy-moenomycin A. In addition, a moenomycin A
carrying an oxygen in the moenocinol-group was found, which is most probably a chemical
degradation product. These new compounds were verified by LC-ESI-IT-MS. (J Am Soc Mass
Spectrom 2006, 17, 1081-1090) © 2006 American Society for Mass SpectrometryMoenomycins, alternatively named bambermy-cins, Flavomycin, and flavophospholipol, area group of structurally very similar phospho-
glycolipid antibiotics produced by several Streptomyces
species, including S. bambergiensis, S. ghanaensis, S.
geysiriensis, and S. ederensis [1–3]. The spectrum of
antibiotic activity of the Flavomycin complex covers
primarily gram-positive microorganisms, such as
staphylococci and streptococci [2, 4]. It is used as
antimicrobial growth promoter of several farm animals
[2] and is an authorized additive for feeding stuffs in the
EU (registration number E 712) [5] and in the USA [6].
The antibiotic activity of the moenomycins is based
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doi:10.1016/j.jasms.2006.04.019on the inhibition of the bacterial cell wall formation [2,
3, 7, 8]. The biosynthesis of the peptidoglycan in the cell
wall involves the assembly of lipid II (the disaccharide
pentapeptide monomer unit that is linked to an unde-
caprenyl phosphate-membrane carrier) from cytoplas-
mic intermediates, the translocation of lipid II through
the cytoplasmic membrane to the outer surface fol-
lowed by the incorporation of the disaccharide pen-
tapeptide monomer units into the growing glycan
chains (transglycosylation) and finally the formation of
the peptide cross-bridges to the pre-existing pepti-
doglycans in the mature cell wall (transpeptidation) [8].
The moenomycins interfere with the transglycosylation
reaction by inhibition of some membrane-bound, non-
penicillin-binding, monofunctional glycosyltransferases
(Mgts) and some class A high-molecular-mass penicil-
lin-binding proteins (HMM-PBPs) [2, 3, 7–12]. Class A
HMM-PBPs, such as the PBP1b from Escherichia coli, are
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sylation reaction and the transpeptidation reaction.
While -lactam antibiotics bind covalently to an active-
site serine in the transpeptidase domain of this bifunc-
tional enzymes, moenomycins are assumed to act as
competitive inhibitors at the transglycosylase domain
[3, 7–10]. Although several antibiotics interfere with the
transglycosylation reaction, moenomycins are the only
compounds known to date that directly interact with
the transglycosylases rather than bind to their sub-
strates [3]. The moenomycins therefore represent an
interesting template for the design of new antibiotic
drugs [3, 7, 8, 13, 14], which are highly desired because
of the problem of bacterial resistance [14 –18].
Now, five major components of the Flavomycin
complex have been structurally characterized, namely
moenomycin A [19 –21], moenomycin A12 [22], moeno-
mycin C4 [23], moenomycin C3 [23], and moenomycin
C1 [24]. They all consist of a central oligosaccharide part
(B–F) that is, on the one side linked to an isoprenoid-
like C25-alcohol (I) via a phosphodiester group (G) and
a 2,3-dihydroxypropanoic acid (glyceric acid) group (H)
and, on the other side to a 2-hydroxy-5-oxo-1-cyclo-
penten-1-yl group (A) (Scheme 1). From structure-
activity relationship analysis, it has been found that
moenomycin trisaccharides containing the units C, E, F,
G, H, and I are the smallest fragments that show
antibiotic activity in vivo, whereas moenomycin disac-
charides containing the units E–I still act as transglyco-
sylase inhibitors in vitro [3, 7–9, 12, 25]. The isoprenoid-
like C25-alcohol [26], named moenocinol, seems to be
required for the binding of the moenomycin antibiotics
to the cytoplasmic membrane [27], whereas the units E,
F, and H are concluded to form a polar binding epitope
that is recognized by the donor binding site of the
transglycosylases [3, 7–9, 19, 28]. In addition to the five
known constituents of the Flavomycin complex, struc-
turally related moenomycin-type antibiotics, including
the prasinomycins, the diumycins (macarbomycins),
Scheme 1. Structure of the five previously cha
constitute the Flavomycin complex.ensanchomycin, prenomycin, teichomycin, pholipomy-cin, AC326-, 11837 RP, 8036 RP (quebemecin), and
19402 RP, have been found [3, 23, 29, 30].
The chemical structures of the five major compo-
nents of the Flavomycin complex have been established
by 13C-NMR spectroscopy and fast-atom-bombardment
(FAB)-mass spectrometry (MS) of the purified com-
pounds [20 –24] and were later confirmed by 1H-NMR
spectroscopy [31]. Subramaniam-Niehaus et al. [32]
have used liquid chromatography-electrospray ioniza-
tion-mass spectrometry (LC-ESI-MS) to confirm the
presence of these five compounds in the culture filtrate
of S. ghanaensis. Recently, Eichhorn and Aga [6] isolated
the moenomycin antibiotics from medicated chicken
feed and investigated the fragmentation behavior of the
five known constituents by positive and negative ion
mode LC-ESI-ion trap (IT)-MS.
The focus of our study is on the detailed mass
spectrometric characterization of the Flavomycin com-
plex and the identification of novel natural moenomy-
cin compounds by, for the first time, matrix-assisted
laser desorption/ionization-ion trap/reflectron time-of-
flight multistage mass spectrometry (MALDI-IT/
RTOF-MS) and additional LC-ESI-IT-MS. The applica-
bility of the MALDI-IT/RTOF-MS technique to the
structural analysis of oligosaccharides and glycopep-
tides has been described in previous work [33–38] and
is extended to the class of medically relevant phospho-
glycolipids.
Experimental
Materials
Flavomycin was obtained from Hoechst Roussel Vet
(Wiesbaden, Germany). The MALDI matrix compound
2,4,6-trihydroxyacetophenone monohydrate (2,4,6-
THAP) and the additive diammonium hydrogen citrate
were obtained from Fluka (Buchs, Switzerland). Am-
monium acetate was supplied by Sigma-Aldrich (St.
ized moenomycin antibiotics that are known toracterLouis, MO). Sodium chloride, methanol, and water with
1083J Am Soc Mass Spectrom 2006, 17, 1081-1090 MALDI-IT/RTOF-MS OF MOENOMYCIN ANTIBIOTICSa specific conductivity of 1 Scm1 were purchased
from Merck (Darmstadt, Germany).
MALDI Sample Preparation
Sample preparation was performed on microtiter for-
mat stainless-steel target slides from Shimadzu Biotech-
Kratos Analytical (Manchester, UK). Flavomycin was
dissolved in 20 mM aqueous ammonium acetate to 0.1
gL1. For negative ion mode measurements, 0.4 L of
0.2 M aqueous diammonium hydrogen citrate, 0.6 L of
the Flavomycin solution, and 0.8 L of a solution of 20
gL1 2,4,6-THAP in methanol were mixed on the target
in the given order and dried at room temperature in a
gentle stream of air. For positive ion mode measure-
ments, either the same preparation method was used or
the 0.2 M aqueous diammonium hydrogen citrate was
replaced by 20 mM aqueous sodium chloride.
MALDI-IT/RTOF Mass Spectrometry
The MALDI-MS1 and MALDI-low-energy CID-MSn
(n  2–3) measurements were performed on an
AXIMA-QIT (Shimadzu Biotech-Kratos Analytical).
This hybrid-instrument consists of a 3D quadrupole
ion trap coupled to a double-stage gridless reflectron
TOF analyzer [39, 40]. The AXIMA-QIT is equipped
with a pulsed nitrogen laser, having a wavelength of
337 nm and a pulse width (FWHM) of about 4 ns, and
an integrated 1 GHz recorder. The total acceleration
voltage in negative and positive ion mode was 4 kV.
The ion trap was continuously supplied with helium
at a pressure of 5  105 mbar to allow collisional
cooling of the trapped ions. In addition, a short pulse
of argon was injected into the IT immediately before
the ion introduction to enhance the ion-cooling effi-
ciency and immediately before the radio frequency-
induced precursor ion excitation to enhance the frag-
mentation efficiency during CID in MSn-mode. CID
spectra were acquired by averaging 1024–5041 uns-
elected single laser shots using a precursor ion selec-
tion width of 1/70, 1/250, or 1/1000 of the precursor
ion mass in MS2 and 1/70 or 1/250 of the precursor
ion mass in MS3. External mass calibration using
fullerite (Shimadzu Biotech-Kratos Analytical) or the
synthetic peptide P14R (Sigma-Aldrich) was per-
formed for mass assignment.
LC-ESI-IT Mass Spectrometry
The measurements were carried out on an Agilent 1100
HPLC (Agilent Technologies, Waldbronn, Germany)
coupled to a ThermoFinnigan LCQ Deca XP ion trap
mass spectrometer (ThermoFinnigan, San Jose, CA)
fitted with an orthogonal ESI ion source. Chromato-
graphic separation of the Flavomycin constituents was
performed with a Hypersil ODS-column of 200  2.1
mm dimension having a particle size of 5 m (Thermo
Electron, Waltham, MA), and at a column temperatureof 50 °C. The solvents used were 10 mM ammonium
acetate in doubly distilled water (Solvent A) and 10 mM
ammonium acetate in methanol (Solvent B). The gradi-
ent was performed from 75–95% Solvent B for 25 min at
a flow rate of 250 Lmin1. The ESI source was oper-
ated in negative ion mode with a source temperature of
200 °C and a spray voltage of 4 kV. The instrument was
tuned for maximum transmission of doubly-charged
negative ions ([M  2H]2) and the scan-range was set
to m/z 300–1650.
Results and Discussion
MALDI-IT/RTOF-MS1
Positive ion mode MALDI mass spectra of the Flavo-
mycin complex turned out to be of limited use for the
characterization of the individual constituents. In
contrast to ESI measurements, [M  H] ions could
not be observed with MALDI, which is related to
their low stability [6]. Series of alkali adduct ions
ranging from [M  Na] up to [M  2Na  2K 
3H] were detected instead, which resulted in a
complicated peak pattern and the overlapping of the
isotopic distributions of ions from different com-
pounds. The addition of small amounts of sodium
chloride (20 mM aqueous sodium chloride was added
instead of the 0.2 M aqueous diammonium hydrogen
citrate) to suppress potassium adduct ion formation
did not improve the situation sufficiently. However,
it has to be mentioned that MSn experiments of the [M
 2Na  H] ion of moenomycin A, which was the
most abundant species, have yielded a large variety
of highly abundant fragment ions that would in
principle facilitate the structural characterization of
this class of compounds (data not shown).
Negative ion mode MALDI measurements using
the matrix substance 2,4,6-THAP and diammonium
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Figure 1. Negative ion mode MALDI-IT/RTOF mass spectrum
of the Flavomycin complex showing the [M  H] ions of the five
known major constituents, namely moenomycin A, moenomycin
A12, moenomycin C4, moenomycin C3, and moenomycin C1, and
five not yet characterized compounds.hydrogen citrate as additive (to suppress alkali ad-
1084 ZEHL ET AL. J Am Soc Mass Spectrom 2006, 17, 1081-1090duct ion formation), on the other hand, gave rather
clean mass spectra showing nearly exclusively [M 
H] ions (Figure 1). Beside the [M  H] ions of the
five known major components of the Flavomycin
complex, several other ions were detected, e.g., at m/z
1404.61, m/z 1484.64, m/z 1485.63, and m/z 1596.66. A
consequence of the coupling of vacuum MALDI with
an ion trap device is the enhanced probability of post
source decay in the larger time frame inherent to the
trapping process, resulting in the occasionally ob-
served fragmentation of the precursor ions already in
MS1 [33, 41]. Indeed, the rather labile phosphoglyco-
lipids exhibited prompt decay in MS1 as well (most
abundant fragment ion/deprotonated molecular ion
ratio of approximately 2/1). However, in the case of
the moenomycins, all abundant fragment ions were
below m/z 1200 and, thus, did not interfere with the
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Figure 2. Negative ion mode MALDI-IT/RTOF product ion
spectra of moenomycin A: (a) MS2 spectrum of the [M  H] ion
(m/z 1581 ¡); (b) same spectrum amplified by a factor of 42 to
show the low abundant product ions; (c) MS3 spectrum of the
main product ion (m/z 1581 ¡ 1152 ¡).analysis of the intact species.Moenomycin A
Moenomycin A [21], the main constituent of the Flavo-
mycin complex (40–80%), contains a pentasaccharide
core (B, C, D, E, F) with a glucopyranosyl residue (D)
that is (1¡6)-linked to the 2-(acetylamino)-2-deoxy-
glucopyranosyl group (E) (Scheme 1). The correspond-
ing [M  H] ion was detected at m/z 1580.66 (calc. m/z
1580.65) representing the most abundant species (Fig-
ure 1). The low-energy CID spectrum of the precursor
ion m/z 1581 shows one predominant product ion at m/z
1152 representing the loss of the moenocinol group (I)
and the 2,3-dihydroxypropanoic acid group (H) (Figure
2a and Scheme 2). In addition, only four other ions were
detected with a relative intensity 1% of the base beak.
These ions have all lost the units H and I, and, in
addition, a HN¢C¢O group (m/z 1109), the carbamate
group (NH2COOH) from unit F (m/z 1091), a HN¢C¢O
as well as the PO3H group (m/z 1029), or the whole
uronamide-derived unit F (m/z 902). The formation of
the latter ion by an internal residue loss requires a
rearrangement reaction, which has been described for
several compounds [42– 46]. One possible structure of
the ion at m/z 902, which is an alternative to the one
proposed by Eichhorn and Aga [6], is given in Scheme
2. Most of the interesting product ions in MS2 were
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Scheme 2. Proposed low-energy CID fragmentation pathway for
the [MH] ion of moenomycin A (MS2;m/z 1581¡). Additional
water and ammonia losses have been omitted.
1085J Am Soc Mass Spectrom 2006, 17, 1081-1090 MALDI-IT/RTOF-MS OF MOENOMYCIN ANTIBIOTICSobserved in the intensity-range below 1% of the base
peak, but still with a good S/N ratio (Figure 2b and
Scheme 2). The MS3-spectrum of the main product ion
at m/z 1152 showed mainly the same ions that were
already present in MS2, with the exception of a product
ion at m/z 962, which is assumed to originate from a
0,2X-type cross-ring cleavage of unit F, and a low mass
product ion at m/z 329, assigned to the phosphorylated
unit F (Figure 2c and Scheme 3). The proposed frag-
mentation pathways given in Scheme 2 and Scheme 3
have been corroborated by additional MS3 experiments
of the precursor ions atm/z 1109,m/z 1091,m/z 1029, and
m/z 902 (data not shown).
From the whole variety of observed fragmentations,
ten characteristic product ions have been selected that
allow the mass determination of each individual build-
ing unit of the moenomycin antibiotics (Scheme 4 and
Table 1). The discussion of the CID-behavior of the
other compounds of the Flavomycin complex is mainly
restricted to these selected product ions to reduce
redundancy.
Moenomycin A12
Moenomycin A12 [22] also contains the pentasaccharide
core with the glucopyranosyl residue (D), but in con-
trast to moenomycin A, the 4-C-methyl group in the
uronamide-derived unit F is absent (Scheme 1). The
corresponding [M  H] ion was detected with low
abundance at m/z 1566.66 (calc. m/z 1566.64) (Figure 1).
The CID-behavior observed in MS2 and in MS3 of the
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Scheme 3. Proposed low-energy CID fragmentation pathway for
the main product ion of moenomycin A (MS3;m/z 1581¡ 1152¡).
Additional water and ammonia losses have been omitted.main product ion P1 (m/z 1138) was very similar com-pared to moenomycin A. All product ions containing
the unit F (P1, P3, P7, P8, P9, and P10; P5 was only
observed with S/N 3), were detected at 14 Da,
whereas P4 and P6 had identical masses compared to
moenomycin A (Table 1). However, the influence of the
4-C-methyl group or, more probably, of the different
configuration of unit F (D-galacto rather than D-gluco)
[31], was apparent from significantly increased relative
intensities of those product ions originating from the
cleavage of bonds around unit F, such as product ions
of the type P1-HN¢C¢O, P1-NH2COOH, and P6 (but
not P4).
Moenomycin C4, C3, and C1
In moenomycin C4 [23], the glucopyranosyl residue (D)
is absent, whereas the remaining structure is identical to
moenomycin A. Moenomycin C3 [23] and moenomycin
C1 [24] both contain a 2-(acetylamino)-2,6-dideoxyglu-
copyranosyl group as unit E and moenomycin C1
furthermore lacks the 4-C-methyl group in unit F
(Scheme 1). The corresponding [M  H] ions were
detected at m/z 1418.62 (calc. m/z 1418.60), 1402.61 (calc.
m/z 1402.61), and 1388.60 (calc. m/z 1388.59), respec-
tively (Figure 1). The CID behavior observed in MS2
and in MS3 was in all three cases very similar to
moenomycin A, although the main product ions (P1)
were not that much predominant in MS2. Moenomycin
C4 and moenomycin C3 yielded product ions P2, P3,
and P5with identical masses compared to moenomycin
A. All other product ions contain the unit E and were
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Scheme 4. Ten selected key product ions of moenomycin-type
structures.
1086 ZEHL ET AL. J Am Soc Mass Spectrom 2006, 17, 1081-1090therefore detected at162 Da (C6H10O5) and178 Da
(C6H10O6), respectively (Figure 3a and Table 1). Those
product ions of moenomycin C1 containing unit F (P3
and P5) were shifted by 14 Da due to the missing
4-C-methyl group, those containing unit E (P4 and P6)
were observed at 178 Da, and those possessing both
units (P1, P7, P8, and P9) were detected at 192 Da
(Figure 3b and Table 1). The product ions P1-HN¢C¢O,
P1-NH2COOH and P6 were found with higher relative
intensity in moenomycin C1 compared to moenomycin
C3, showing again the effect of the different configura-
tion of unit F. The product ion P4, on the other hand,
was observed to be much less prominent in moenomy-
cin C1 and C3 compared to the other three moenomy-
cins, indicating that the oxygen at position 6 of unit E
favors the rearrangement reaction that causes the inter-
nal loss of unit F.
4F-Demethyl-6E-O-de--D-Glucopyranosyl-
Moenomycin A
The measured isotopic pattern of moenomycin C3 has
been found to strongly differ from the theoretical dis-
tribution, which could only be explained by the pres-
ence of a second component, whose monoisotopic peak
overlaps with the third isotopic peak of moenomycin C3
at m/z 1404.61 (Figure 1). Indeed, product ions not
related to moenomycin C3 were observed in MS
2 and
MS3 spectra obtained with a precursor ion selection
width in MS2 of 1/250 of the precursor ion mass,
corresponding to 5.6 Th (data not shown). These prod-
uct ions disappeared when the precursor ion selection
width had been reduced to 1/1000 of the precursor ion
mass (corresponding to 1.4 Th), which is feasible with
the applied instrument at the expense of sensitivity, so
that only the first two isotopes of moenomycin C3 were
isolated (Figure 3a). The relative abundance of these
product ions was, on the other hand, strongly enhanced
when only the isotopes at 1405.60 and 1406.58 were
isolated and fragmented (Figure 3c). This way, several
Table 1. Observed monoisotopic m/z-values for the [M  H]
4) of the moenomycin antibiotics
Compound [M  H] P1 P2 P3
Moenomycin A 1580.66 1152 507 757
Moenomycin A12 1566.66 1138 n.d. 743
Moenomycin C4 1418.62 990 507 757
Moenomycin C3 1402.61 974 507 757
Moenomycin C1 1388.60 960 507 743
m/z 1405 1404.61 976 n.d. 743
m/z 1485 1484.64 1056 507 757
m/z 1486 1485.63 1057 507 757
m/z 1597a 1596.66 1168 n.d. 757
m/z 1597b 1596.66 1152 n.d. n.d.
n.d., not detected; -, not possible.product ions belonging to the component at m/z 1404.61300 400 500 600 700 800 900 1000
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Figure 3. Negative ion mode MALDI-IT/RTOF product ion
spectra (MS3) of (a) moenomycin C3 (m/z 1403 ¡ 974 ¡); (b)
moenomycin C1 (m/z 1389 ¡ 960 ¡); (c) the new compound
assigned as 4F-demethyl-6E-O-de--D-glucopyranosyl-moenomy-
cin A (m/z 1405 ¡ 976 ¡). The latter spectrum (c) was obtained
from the second and third isotopes of 4F-demethyl-6E-O-de--D-
glucopyranosyl-moenomycin A, but also contains product ionsions and selected low-energy CID product ions (defined in Scheme
m/z
P4 P5 P6 P7 P8 P9 P10
902 329 822 694 881 1039 990
902 n.d. 822 680 867 1025 976
740 329 660 532 719 877 -
724 329 644 516 703 861 -
724 315 644 502 689 847 -
740 n.d. 660 n.d. 705 863 -
806 329 726 694 881 - n.d.
807 329 727 694 881 - 895
918 n.d. 838 694 897 1055 1006
902 n.d. 822 694 n.d. 1039 n.d.derived from the fourth and fifth isotopes of moenomycin C3.
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tra of the pure compound were not obtained. The
product ions P1, P8, and P9 were detected at 2 Da
compared to moenomycin C3, indicating that groups A,
B, H, and I are identical. P3 was found at m/z 743
instead of m/z 757, which points out the absence of the
4-C-methyl group in unit F, such as in the case of
moenomycin A12 and moenomycin C1. Consequently,
P4 and P6 had a mass shift of 16 Da compared to
moenomycin C3 (Figure 3c and Table 1). Although P7
could not be detected with a sufficient S/N-ratio, the
product ion P7-HN¢C¢O was observed at m/z 475,
which allows the localization of the additional oxygen
at unit E. This lets us assume the presence of the
2-(acetylamino)-2-deoxyglucopyranosyl group as unit
E, such as in the case of moenomycin C4. Thus, the new
compound at m/z 1404.61 is assigned as 4F-demethyl-
6E-O-de--D-glucopyranosyl-moenomycin A. This
compound is a very likely (by)product of the moeno-
mycin biosynthesis considering the known variability
of both, the 4-C-methyl group in unit F and the 6-hy-
droxy group in unit E.
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Figure 4. Mixed negative ion mode MALDI-IT/RTOF product
ion spectrum (MS2) of the new compounds assigned as 6B-N-
de(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-moenomycin A and 6B-
hydroxy-6B-de[N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)amino]-
moenomycin A (m/z 1485/1486 ¡).
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Figure 5. Mixed negative ion mode MALDI-IT/RTOF product
ion spectrum (MS2) of the two new isobaric compounds assigned
as 6C-hydroxy-moenomycin A (product ions labeled Pxa) and
oxidized moenomycin A (product ions labeled Pxb) (m/z 1597¡).
Only the m/z-range 600–1200 is shown.6B-N-de(2-Hydroxy-5-oxo-1-Cyclopenten-1-yl)-
Moenomycin A and 6B-Hydroxy-6B-de[N-(2-
Hydroxy-5-oxo-1-Cyclopenten-1-yl)Amino]-
Moenomycin A
Two other novel components of the Flavomycin com-
plex were detected at 1484.64 Da and 1485.63 Da (Figure
1). Due to the strong overlap of the isotopic patterns,
both components have been isolated and subjected to
CID experiments at once (Figure 4). They yielded prod-
uct ions of the type P2, P3, P5, P7, and P8 that had
identical masses compared to moenomycin A. Only
product ions containing the unit B, namely P1, P4, and
P6, where detected at 96 Da and 95 Da (Table 1).
From these results, it was concluded that the new
compounds are moenomycin A-like structures that lack
the chromophore unit A. In the less abundant com-
pound at m/z 1484.64 Da, unit B remains as a galacto-
pyranuronamid. This 6B-N-de(2-hydroxy-5-oxo-1-cy-
0
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b) EIC (m/z = 789.5-790.5)
c) EIC (m/z = 782.5-783.5)
d) EIC (m/z = 708.5-709.5)
e) EIC (m/z = 700.5-701.5)
f) EIC (m/z = 693.5-694.5)
g) EIC (m/z = 701.5-702.3)
h) EIC (m/z = 741.5-742.1)
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0
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4.18
i) EIC (m/z = 742.3-743.0) 
j) EIC (m/z = 797.5-798.5)
Figure 6. Negative ion mode LC-ESI-IT-MS (a) total ion chro-
matogram (TIC) of the Flavomycin complex and (b)–(j) extracted
ion chromatograms (EIC) of the [M  2H]2 ions of the 10
analyzed constituents. The displayed m/z-traces correspond to (b)
moenomycin A, (c) moenomycin A12, (d) moenomycin C4, (e)
moenomycin C3, (f) moenomycin C1, (g) 4F-demethyl-6E-O-de--
D-glucopyranosyl-moenomycin A (RT  11.00 min), and moeno-
mycin C3 (RT  11.25 min), (h) 6B-N-de(2-hydroxy-5-oxo-1-
cyclopenten-1-yl)-moenomycin A, (i) 6B-hydroxy-6B-de[N-(2-
hydroxy-5-oxo-1-cyclopenten-1-yl)amino]-moenomycin A, and (j)
6C-hydroxy-moenomycin A (RT  11.28 min) and oxidized
moenomycin A (RT  4.18 min).clopenten-1-yl)-moenomycin A has been previously
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A and was shown to be antibiotically active [47]. In the
compound at m/z 1485.63 Da, unit B is assumed to be
converted to a galactopyranuronic acid. Although the
fragmentation pathway of these compounds is still
nearly identical compared to moenomycin A, the miss-
ing 2-hydroxy-5-oxo-1-cyclopenten-1-yl-group has a
strong effect on the relative intensities of some product
ions (Figure 4). The most prominent effect was observed
for P8 and other product ions originating from the loss
of unit B (e.g., P4  B at m/z 631 and [M  B  H] at
m/z 1310), which were detected with strongly enhanced
relative intensities. Surprisingly, the presence of the
terminal galactopyranuronic acid, but not the galacto-
pyranuronamid group, had also a strong favoring effect
toward the loss of unit D, which can be seen for P10 or
the loss of unit D from the intact molecule ([M  D 
H] at m/z 1324).
The presence of the two moenomycin A-like com-
pounds lacking the chromophore unit A, which might
either originate from an incomplete biosynthesis or
from a degradation of the mature moenomycin A,
suggests the presence of the corresponding compounds
from the other known moenomycins as well. Indeed,
very small peaks could be found at 96/95 Da of
moenomycin A12, moenomycin C4, moenomycin C3,
and moenomycin C1 in MS
1, but the abundance of these
ions was too low to obtain useful MS2 spectra.
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Scheme 5. Structure of the ten characterized moenomycin anti-
biotics that constitute the Flavomycin complex. The nature of the
six variable positions (R1–R6) is given in Table 2.
Table 2. The nature of the six variable positions (R1  R6 in Sch
antibiotics that constitute the Flavomycin complex
Compound R1 R2
Moenomycin A HI CH3
Moenomycin A12 HI OH
Moenomycin C4 HI CH3
Moenomycin C3 HI CH3
Moenomycin C1 HI OH
m/z 1405 HI OH
m/z 1485 HI CH3
m/z 1486 HI CH3
m/z 1597a HI CH3
m/z 1597b oxidized HI CH36C-Hydroxy-Moenomycin A and Oxidized
Moenomycin A
Two other novel, isobaric compounds of the Flavomy-
cin complex were discovered at 1596.66 Da (Figure 1).
The more abundant of these two constituents yielded
only two product ions with identical masses compared
to moenomycin A, namely P3 and P7, which contain the
units D–I (P2 and P5 were not detected with sufficient
S/N). All other product ions, including P9 and P8, had
a mass shift of16 Da compared to moenomycin A (see
Figure 5 and m/z 1597a in Table 1), which means that
units A and B also have the same mass as in moeno-
mycin A. Consequently, unit C must carry a modifica-
tion that causes the observed mass shift of16 Da. This
finding is also corroborated by a number of other
product ions, such as the one originating from further
fragmentation of P4 (analogous to Scheme 2). Although
a more exact localization was not possible from the
observed low-energy CID product ions, we assume that
the unit C in this component carries a hydroxy-group in
position 6. The presence of 6C-hydroxy-moenomycin A
in the Flavomycin complex is also not completely
surprising, taking into account the similarity of unit C
to unit E, and the presence of a 2-(acetylamino)-2-
deoxyglucopyranosyl group as unit C in the moenomy-
cin-type antibiotics pholipomycin (6E-O-de--D-
glucopyranosyl-6C-hydroxy-moenomycin A) from
Streptomyces lividoclavatus [23, 29] and AC326- from
Actinomyces AC326 [30]. The latter is structurally
identical to the proposed 6C-hydroxy-moenomycin A
except that it possesses a cyclized moenocinol deriv-
ative.
The second compound at m/z 1596.66 Da yielded a
series of product ions in MS2, namely P1, P4, P6, and P9,
which cannot originate from 6C-hydroxy-moenomycin
A but are identical to moenomycin A (see Figure 5 and
m/z 1597b in Table 1). These product ions clearly show
that the units A–G have the same mass as in moeno-
mycin A and, although P2 and P3 could not be detected
due to the low abundance of this constituent, suggest
that unit H or I are modified to give a mass shift of 16
Da. We assume that this compound is a chemical
5) in the structure of the ten characterized moenomycin
R3 R4 R5 R6
OH D H A
H D H A
OH OH H A
OH H H A
H H H A
H OH H A
OH D H NH2
OH D H OH
OH D OH AemeOH D H A
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from oxidation of the moenocinol group (I) [48].
LC-ESI-IT Mass Spectrometry
The negative ion mode LC-ESI-IT-MS total ion chro-
matogram (TIC) of the Flavomycin complex and the
extracted ion chromatograms (EIC) of the [M  2H]2
ions of the 10 analyzed constituents are shown in Figure
6. The different components of the mixture were only
partially separated by C18-RP-chromatography under
the given conditions. The major component, moenomy-
cin A, eluted at 11.06 min (Figure 6b). Moenomycin C3
(Figure 6e, 11.28 min), 4F-demethyl-6E-O-de--D-glu-
copyranosyl-moenomycin A (Figure 6g, 11.00 min),
6B-hydroxy-6B-de[N-(2-hydroxy-5-oxo-1-cyclopenten-
1-yl)amino]-moenomycin A (Figure 6i, 11.30 min), and
6C-hydroxy-moenomycin A (Figure 6j, 11.28 min) were
barely separated from moenomycin A and from each
other. Moenomycin C4 (Figure 6d, 11.83 min) and
6B-N-de(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-moeno-
mycin A (Figure 6h, 13.84 min) were more strongly
retained in the LC column than the above mentioned
compounds. Moenomycin A12 (Figure 6c, 10.50 min)
and moenomycin C1 (Figure 6f, 10.60 min) (co)-eluted
before moenomycin A and moenomycin C3, respec-
tively, which was expected due to the missing 4F-
methyl-group. The same effect was observed for 4F-
demethyl-6E-O-de--D-glucopyranosyl-moenomycin
A, which eluted before moenomycin C4. The low
abundant compound eluting at 4.18 min (Figure 6j)
was subjected to MS2 and this experiment confirmed
that this peak represents the oxidized moenomycin
A. The large reduction in the retention time observed
for this compound further corroborates that this
constituent possesses a free hydroxy-group in the
otherwise hydrophobic isoprenoid-like substructure
(unit I). Interestingly, an additional hydroxy-group in
the per se polar part of this amphiphilic molecule,
either on unit E (moenomycin C1 versus 4F-demethyl-
6E-O-de--D-glucopyranosyl-moenomycin A andmoeno-
mycin C3 versus moenomycin C4) or on unit C (moeno-
mycin A versus 6C-hydroxy-moenomycin A), causes a
stronger retention.
Although not all components could be baseline-
separated under the applied conditions, the observed
elution order of the constituents of the moenomycin
complex on the reversed-phase column might be help-
ful in future studies aiming on the isolation and further
characterization of these structures. The differences in
the retention time of the postulated new constituents
compared to the known constituents give clear evidence
that the corresponding MALDI-generated ions repre-
sent true deprotonated molecular ions instead of frag-
ment ions originating from the in- or post-source decay
of moenomycins with higher molecular masses.Conclusions
Negative ion mode multistage low-energy CID using a
MALDI-IT/RTOF-MS, which allows detection of the
fragment ions in the last CID stage in the high-resolu-
tion mode, and negative ion mode LC-ESI-IT-MS were
used for the analysis of the constituents of Flavomycin,
which is a mixture of structurally closely related sub-
stances. Particularly, the negative ion MALDI-MS mode
turned out to be extremely useful for the characteriza-
tion of the very complex phosphoglycolipids. Based on
the derived fragmentation pathway of the [M  H]
ions of the five known compounds constituting the
Flavomycin complex, namely moenomycin A, moeno-
mycin A12, moenomycin C4, moenomycin C3, and
moenomycin C1, four not yet described constituents
could be characterized (Scheme 5 and Table 2). 4F-
demethyl-6E-O-de--D-glucopyranosyl-moenomycin A
and 6C-hydroxy-moenomycin A are most probably
(by)products of the moenomycin biosynthesis. They
might be of interest in the elucidation of the enzymatic
assembly of this class of compounds. In the case of the
two structures lacking the chromophore unit A, namely
6B-N-de(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-moeno-
mycin A and 6B-hydroxy-6B-de[N-(2-hydroxy-5-oxo-1-
cyclopenten-1-yl)amino]-moenomycin A, it cannot be
unambiguously stated whether this compounds are
biosynthetic intermediates or degradation products.
Chemically derived 6B-N-de(2-hydroxy-5-oxo-1-cyclo-
penten-1-yl)-moenomycin A has already been shown to
be antibiotically active [47]. From structure-activity
relationship analysis of the moenomycins [3, 7–9, 12, 25]
and the activity of pholipomycin [23, 29] and AC326-
[30] it can be concluded that the other three above
mentioned substances are potent antibiotics as well.
Furthermore, a moenomycin A carrying an oxygen in
the moenocinol-group was found, which is most prob-
ably a chemical degradation product. This compound is
assumed to have a comparable low, if any, antibiotic
activity [48].
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